Skip to content

Study · Randomized controlled trial · n = 36 · 2004

8 results

[A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke].

Skvortsova VI, Stakhovskaia LV, Gubskiĭ LV, Shamalov NA, Tikhonova IV, Smychkov AS

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2004Cited by 15 (Europe PMC)

PMID15559222 (opens in a new tab)PepBankPUB-15559222
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin significantly reduced MRI ischemic focus volume versus placebo on day 3.

    In plain wordsIn stroke patients, Cerebrolysin reduced the MRI ischemic focus volume more than placebo on day 3.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseMRI ischemic focus volume at day 3
    Study

    n = 36

    Comparator
    placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 ml/d · 10 daysAs given in this study (human).

    Measurements

    P value
    < 0.05
    versus Placebo

    Source sentences

    Summary
    The significant reduction in the volume of MRI ischemic focus was shown in both Cerebrolysin groups (p < 0.05 vs Placebo) on day 3.
    2 context sentences
    Summary · context
    Thirty-six patients with ischemic stroke in carotid artery territory aged 45-85 years, were eligible for inclusion in the trial if they were admitted to the hospital within the first 12h after stroke onset.
    Summary · context
    Patients were randomly and blindly assigned to placebo (n = 12) or 1 or 2 dosages of Cerebrolysin: 10 ml/d (n = 12) and 50 ml/d (n = 12) for 10 days with concomitant standard basic treatment in each group.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin showed a tendency toward faster Clinical Global Impression improvement by day 30.

    In plain wordsIn stroke patients, Cerebrolysin showed a tendency toward faster improvement on the Clinical Global Impression Scale.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseClinical Global Impression improvement
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml/d · 10 daysAs given in this study (human).

    Source sentences

    Summary
    A quantitative time-related analysis of the dynamics of neurological deficit revealed the tendency towards acceleration of improvement assessed by the Clinical Global Impression Scale and NIHSS in both Cerebrolysin groups by 30 day of the treatment.
    2 context sentences
    Summary · context
    Thirty-six patients with ischemic stroke in carotid artery territory aged 45-85 years, were eligible for inclusion in the trial if they were admitted to the hospital within the first 12h after stroke onset.
    Summary · context
    Patients were randomly and blindly assigned to placebo (n = 12) or 1 or 2 dosages of Cerebrolysin: 10 ml/d (n = 12) and 50 ml/d (n = 12) for 10 days with concomitant standard basic treatment in each group.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin showed a tendency toward faster NIHSS improvement by day 30.

    In plain wordsIn stroke patients, Cerebrolysin showed a tendency toward faster improvement on the NIHSS scale.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNIHSS improvement
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml/d · 10 daysAs given in this study (human).

    Source sentences

    Summary
    A quantitative time-related analysis of the dynamics of neurological deficit revealed the tendency towards acceleration of improvement assessed by the Clinical Global Impression Scale and NIHSS in both Cerebrolysin groups by 30 day of the treatment.
    2 context sentences
    Summary · context
    Thirty-six patients with ischemic stroke in carotid artery territory aged 45-85 years, were eligible for inclusion in the trial if they were admitted to the hospital within the first 12h after stroke onset.
    Summary · context
    Patients were randomly and blindly assigned to placebo (n = 12) or 1 or 2 dosages of Cerebrolysin: 10 ml/d (n = 12) and 50 ml/d (n = 12) for 10 days with concomitant standard basic treatment in each group.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin showed a tendency toward faster Clinical Global Impression improvement by day 30.

    In plain wordsIn stroke patients, Cerebrolysin showed a tendency toward faster improvement on the Clinical Global Impression Scale.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseClinical Global Impression improvement
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 ml/d · 10 daysAs given in this study (human).

    Source sentences

    Summary
    A quantitative time-related analysis of the dynamics of neurological deficit revealed the tendency towards acceleration of improvement assessed by the Clinical Global Impression Scale and NIHSS in both Cerebrolysin groups by 30 day of the treatment.
    2 context sentences
    Summary · context
    Thirty-six patients with ischemic stroke in carotid artery territory aged 45-85 years, were eligible for inclusion in the trial if they were admitted to the hospital within the first 12h after stroke onset.
    Summary · context
    Patients were randomly and blindly assigned to placebo (n = 12) or 1 or 2 dosages of Cerebrolysin: 10 ml/d (n = 12) and 50 ml/d (n = 12) for 10 days with concomitant standard basic treatment in each group.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin showed a tendency toward faster NIHSS improvement by day 30.

    In plain wordsIn stroke patients, Cerebrolysin showed a tendency toward faster improvement on the NIHSS scale.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNIHSS improvement
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 ml/d · 10 daysAs given in this study (human).

    Source sentences

    Summary
    A quantitative time-related analysis of the dynamics of neurological deficit revealed the tendency towards acceleration of improvement assessed by the Clinical Global Impression Scale and NIHSS in both Cerebrolysin groups by 30 day of the treatment.
    2 context sentences
    Summary · context
    Thirty-six patients with ischemic stroke in carotid artery territory aged 45-85 years, were eligible for inclusion in the trial if they were admitted to the hospital within the first 12h after stroke onset.
    Summary · context
    Patients were randomly and blindly assigned to placebo (n = 12) or 1 or 2 dosages of Cerebrolysin: 10 ml/d (n = 12) and 50 ml/d (n = 12) for 10 days with concomitant standard basic treatment in each group.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin significantly reduced MRI ischemic focus volume versus placebo on day 3.

    In plain wordsIn stroke patients, Cerebrolysin reduced the MRI ischemic focus volume more than placebo on day 3.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseMRI ischemic focus volume at day 3
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml/d · 10 daysAs given in this study (human).

    Measurements

    P value
    < 0.05
    versus Placebo

    Source sentences

    Summary
    The significant reduction in the volume of MRI ischemic focus was shown in both Cerebrolysin groups (p < 0.05 vs Placebo) on day 3.
    2 context sentences
    Summary · context
    Thirty-six patients with ischemic stroke in carotid artery territory aged 45-85 years, were eligible for inclusion in the trial if they were admitted to the hospital within the first 12h after stroke onset.
    Summary · context
    Patients were randomly and blindly assigned to placebo (n = 12) or 1 or 2 dosages of Cerebrolysin: 10 ml/d (n = 12) and 50 ml/d (n = 12) for 10 days with concomitant standard basic treatment in each group.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke, delta and theta focus size and spread decreased versus placebo (p < 0.05) in 72.7% of patients receiving Cerebrolysin 50 ml/d.

    In plain wordsIn stroke patients on Cerebrolysin 50 ml/d, delta and theta focus size and spread decreased versus placebo in 72.7% of patients.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseDelta and theta focus size and spread
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    50 ml/d · 10 daysAs given in this study (human).

    Measurements

    Patients with decrease
    72.7%
    50 ml/d
    P value
    < 0.05
    versus Placebo

    Source sentences

    Summary
    Acute pharmacological test revealed a decrease (p < 0.05 vs Placebo) of the size and spread of delta and theta foci in 72.7% patients, receiving 50 ml/d of Cerebrolysin.
    2 context sentences
    Summary · context
    Thirty-six patients with ischemic stroke in carotid artery territory aged 45-85 years, were eligible for inclusion in the trial if they were admitted to the hospital within the first 12h after stroke onset.
    Summary · context
    Patients were randomly and blindly assigned to placebo (n = 12) or 1 or 2 dosages of Cerebrolysin: 10 ml/d (n = 12) and 50 ml/d (n = 12) for 10 days with concomitant standard basic treatment in each group.
  8. 08HumanRandomized controlled trialSafety outcome

    In acute ischemic stroke patients, Cerebrolysin provoked no paroxysmal EEG activity.

    In plain wordsIn stroke patients, Cerebrolysin triggered no paroxysmal EEG activity.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableEEG paroxysmal activity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · 10 daysAs given in this study (human).

    Source sentences

    Summary
    In none of the cases, Cerebrolysin treatment provoked any paroxysmal activity on EEG.
    2 context sentences
    Summary · context
    Thirty-six patients with ischemic stroke in carotid artery territory aged 45-85 years, were eligible for inclusion in the trial if they were admitted to the hospital within the first 12h after stroke onset.
    Summary · context
    Patients were randomly and blindly assigned to placebo (n = 12) or 1 or 2 dosages of Cerebrolysin: 10 ml/d (n = 12) and 50 ml/d (n = 12) for 10 days with concomitant standard basic treatment in each group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.